As previously shown, increased expression of RKIP in breast and prostate cancer cells leads to increased sensitization to chemotherapeutic agent as measured by CPT induced apoptosis[11], a similar mechanism may explain the role of RKIP in the resistance to chemotherapeutic agents in CRC patients. Here, PEBP1 is linked to prostate carcinoma.